Skip to main content
Erschienen in:

09.03.2021 | Original Paper

Analysis of causes of death in patients with implanted defibrillators

verfasst von: Herbert Nägele, Eike Gröene, Daniel Stierle, Matthias P. Nägele

Erschienen in: Clinical Research in Cardiology | Ausgabe 6/2021

Einloggen, um Zugang zu erhalten

Abstract

Aims

Implantable cardioverter defibrillators (ICDs) are used for primary or secondary prevention of sudden cardiac death. We sought to clarify prognosis and causes of death after ICD implantation.

Methods and results

A total of 2743 patients with ICDs implanted during 1990–2020 were analyzed. Median age was 68.5 (59.6–74.6) years; 21% women, median left ventricular ejection fraction (LVEF) was 30 (23–35), 52% had an ischemic etiology and 77% had a primary preventive indication. Mortality rate after 10 years was 22, 44, 55, and 72% in the 1st, 2nd, 3rd, and 4th age quartile, respectively. The calculated median sex and age adjusted loss of life years compared to the average German population was 9.7 (6.1–14.0) years. Prognosis was independently related to sex, age, LVEF, and glomerular filtration rate. 713 out of 852 deaths could be classified to a specific cause. Congestive heart failure (CHF) accounted for death in 214 (30%) and sudden death (SD) for 144 patients (20%). Postmortem interrogation of devices in 74 patients revealed VT/VF in 39 and no episodes in 35 patients. Cancer was identified as the cause of death in 121 patients (17% of cases), of which 36 were bronchial carcinomas. 73 (10%) of patients died due to infection. 67 patients (9%) died within 24 h of procedures. Compared to other causes, significantly more life years were lost associated with procedures and SD: 9.3 (5.7–12.9) versus 12.1 (7.4–15.2) and 11.9 (7.6–17.8) years.

Conclusion

Life expectancy of ICD patients is lower than for the general population. Mortality is predominantly due to CHF, but there is still a considerable rate of SD. The occurrence of cancers, most importantly bronchial carcinomas, and infections, warrants protective measures. Some deaths during procedures are possibly preventable. Patients with ICDs comprise a vulnerable cohort, and treatment has to be optimized in many directions to improve prognosis.

Graphic abstract

Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Køber L, Thune JJ, Nielsen JC, Haarbo J, Videbæk L, Korup E, Jensen G, Hildebrandt P, Steffensen FH, Bruun NE, Eiskjær H, Brandes A, Thøgersen AM, Gustafsson F, Egstrup K, Videbæk R, Hassager C, Svendsen JH, Høfsten DE, Torp-Pedersen C, Pehrson S, for the DANISH Investigator (2016) Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med 375:1221–1230CrossRef Køber L, Thune JJ, Nielsen JC, Haarbo J, Videbæk L, Korup E, Jensen G, Hildebrandt P, Steffensen FH, Bruun NE, Eiskjær H, Brandes A, Thøgersen AM, Gustafsson F, Egstrup K, Videbæk R, Hassager C, Svendsen JH, Høfsten DE, Torp-Pedersen C, Pehrson S, for the DANISH Investigator (2016) Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med 375:1221–1230CrossRef
2.
Zurück zum Zitat Packer M (2020) What causes sudden death in patients with chronic heart failure and a reduced ejection fraction? Eur Heart J 41:1757–1763CrossRef Packer M (2020) What causes sudden death in patients with chronic heart failure and a reduced ejection fraction? Eur Heart J 41:1757–1763CrossRef
3.
Zurück zum Zitat Taylor CJ, Ordóñez-Mena JM, Roalfe AK, Lay-Flurrie S, Jones NR, Marshall T, Hobbs FR (2019) Trends in survival after a diagnosis of heart failure in the United Kingdom 2000–2017: population based cohort study. BMJ 364(l223):1–10 Taylor CJ, Ordóñez-Mena JM, Roalfe AK, Lay-Flurrie S, Jones NR, Marshall T, Hobbs FR (2019) Trends in survival after a diagnosis of heart failure in the United Kingdom 2000–2017: population based cohort study. BMJ 364(l223):1–10
4.
Zurück zum Zitat Packer M (1985) Sudden unexpected death in patients with congestive heart failure: a second frontier. Circulation 72:681–685CrossRef Packer M (1985) Sudden unexpected death in patients with congestive heart failure: a second frontier. Circulation 72:681–685CrossRef
6.
Zurück zum Zitat Scrucca L, Santucci A, Aversa F (2007) Competing risk analysis using R: an easy guide for clinicians. Bone Marrow Transplant 40(4):381–387CrossRef Scrucca L, Santucci A, Aversa F (2007) Competing risk analysis using R: an easy guide for clinicians. Bone Marrow Transplant 40(4):381–387CrossRef
7.
Zurück zum Zitat Guandalini GS, Liang JJ, Marchlinski FE (2019) Ventricular tachycardia ablation: past, present, and future perspectives. JACC Clin Electrophysiol 5(12):1363–1383CrossRef Guandalini GS, Liang JJ, Marchlinski FE (2019) Ventricular tachycardia ablation: past, present, and future perspectives. JACC Clin Electrophysiol 5(12):1363–1383CrossRef
8.
Zurück zum Zitat Tseng ZH, Hayward RM, Clark NM, Mulvanny CG, Colburn BJ, Ursell PC, Olgin JE, Hart AP, Moffatt E (2015) Sudden death in patients with cardiac implantable electronic devices. JAMA Intern Med 175(8):1342–1350CrossRef Tseng ZH, Hayward RM, Clark NM, Mulvanny CG, Colburn BJ, Ursell PC, Olgin JE, Hart AP, Moffatt E (2015) Sudden death in patients with cardiac implantable electronic devices. JAMA Intern Med 175(8):1342–1350CrossRef
9.
Zurück zum Zitat Tini G, Bertero E, Alessio A, Sormani MP, Maack C, De Boer RA, Canepa M, Ameri P (2020) Cancer mortality in trials of heart failure with reduced ejection fraction: a systematic review and meta-analysis. J Am Heart Assoc 9(e016309):1–29 Tini G, Bertero E, Alessio A, Sormani MP, Maack C, De Boer RA, Canepa M, Ameri P (2020) Cancer mortality in trials of heart failure with reduced ejection fraction: a systematic review and meta-analysis. J Am Heart Assoc 9(e016309):1–29
10.
Zurück zum Zitat de Berrington GA, Mahesh M, Kim KP, Bhargavan M, Lewis R, Mettler F, Land C (2009) Projected cancer risks from computed tomographic scans performed in the United States in 2007. Arch Intern Med. 169(22):2071–2077CrossRef de Berrington GA, Mahesh M, Kim KP, Bhargavan M, Lewis R, Mettler F, Land C (2009) Projected cancer risks from computed tomographic scans performed in the United States in 2007. Arch Intern Med. 169(22):2071–2077CrossRef
11.
Zurück zum Zitat Hill KD, Einstein AJ (2016) New approaches to reduce radiation exposure. Trends Cardiovasc Med 26(1):55–65CrossRef Hill KD, Einstein AJ (2016) New approaches to reduce radiation exposure. Trends Cardiovasc Med 26(1):55–65CrossRef
12.
Zurück zum Zitat Patz EF Jr, Goodman PC, Bepler G (2000) Screening for lung cancer. N Engl J Med 343(22):1627–1633CrossRef Patz EF Jr, Goodman PC, Bepler G (2000) Screening for lung cancer. N Engl J Med 343(22):1627–1633CrossRef
13.
Zurück zum Zitat de Koning HJ, van der Aalst CM, de Jong PA, Scholten ET, Nackaerts K, Heuvelmans MA, Lammers JJ, Weenink C, Yousaf-Khan U, Horeweg N, van’t Westeinde S, Prokop M, Mali WP, Mohamed Hoesein FAA, van Ooijen PMA, Aerts JGJV, den Bakker MA, Thunnissen E, Verschakelen J, Vliegenthart R, Walter JE, Ten Haaf K, Groen HJM, Oudkerk M (2020) Reduced lung-cancer mortality with volume CT screening in a randomized trial. N Engl J Med 382(6):503–513CrossRef de Koning HJ, van der Aalst CM, de Jong PA, Scholten ET, Nackaerts K, Heuvelmans MA, Lammers JJ, Weenink C, Yousaf-Khan U, Horeweg N, van’t Westeinde S, Prokop M, Mali WP, Mohamed Hoesein FAA, van Ooijen PMA, Aerts JGJV, den Bakker MA, Thunnissen E, Verschakelen J, Vliegenthart R, Walter JE, Ten Haaf K, Groen HJM, Oudkerk M (2020) Reduced lung-cancer mortality with volume CT screening in a randomized trial. N Engl J Med 382(6):503–513CrossRef
14.
Zurück zum Zitat Drozd M, Garland E, Walker AMN, Slater TA, Koshy A, Straw S, Gierula J, Paton M, Lowry J, Sapsford R, Witte KK, Kearney MT, Cubbon RMK (2020) Infection-related hospitalization in heart failure with reduced ejection fraction. A prospective observational cohort study. Circ Heart Failure 13:e006746CrossRef Drozd M, Garland E, Walker AMN, Slater TA, Koshy A, Straw S, Gierula J, Paton M, Lowry J, Sapsford R, Witte KK, Kearney MT, Cubbon RMK (2020) Infection-related hospitalization in heart failure with reduced ejection fraction. A prospective observational cohort study. Circ Heart Failure 13:e006746CrossRef
15.
Zurück zum Zitat Barbagelata E, Cillóniz C, Dominedò C, Torres A, Nicolini A, Solidoro P (2020) Gender differences in community-acquired pneumonia. Minerva Med 111(2):153–165CrossRef Barbagelata E, Cillóniz C, Dominedò C, Torres A, Nicolini A, Solidoro P (2020) Gender differences in community-acquired pneumonia. Minerva Med 111(2):153–165CrossRef
16.
Zurück zum Zitat Strassle PD, Sickbert-Bennett EE, Klompas M, Lund JL, Stewart PW, Marx AH, DiBiase LM, Weber DJ (2020) Incidence and risk factors of non-device-associated pneumonia in an acute-care hospital. Infect Control Hosp Epidemiol 41(1):73–79CrossRef Strassle PD, Sickbert-Bennett EE, Klompas M, Lund JL, Stewart PW, Marx AH, DiBiase LM, Weber DJ (2020) Incidence and risk factors of non-device-associated pneumonia in an acute-care hospital. Infect Control Hosp Epidemiol 41(1):73–79CrossRef
17.
Zurück zum Zitat Kifle Y, Wikner JJ, Zotterman J, Ryden L, Farnebo SNFC (2019) Powered implantable temperature sensor. Conf Proc IEEE Eng Med Biol Soc 2019:4359–4362 Kifle Y, Wikner JJ, Zotterman J, Ryden L, Farnebo SNFC (2019) Powered implantable temperature sensor. Conf Proc IEEE Eng Med Biol Soc 2019:4359–4362
18.
Zurück zum Zitat Poole JE, Olshansky B, Mark DB, Anderson J, Johnson G, Hellkamp AS, Davidson-Ray L, Fishbein DP, Boineau RE, Anstrom KJ, Reinhall PG, Packer DL, Lee KL, Bardy GH, SCD-HeFT Investigators (2020) Long-term outcomes of implantable cardioverter-defibrillator therapy in the SCD-HeFT. J Am Coll Cardiol 76(4):405–415CrossRef Poole JE, Olshansky B, Mark DB, Anderson J, Johnson G, Hellkamp AS, Davidson-Ray L, Fishbein DP, Boineau RE, Anstrom KJ, Reinhall PG, Packer DL, Lee KL, Bardy GH, SCD-HeFT Investigators (2020) Long-term outcomes of implantable cardioverter-defibrillator therapy in the SCD-HeFT. J Am Coll Cardiol 76(4):405–415CrossRef
19.
Zurück zum Zitat Cleland JGF, Hindricks G, Petrie M (2019) The shocking lack of evidence for implantable cardioverter defibrillators for heart failure; with or without cardiac resynchronization. Eur Heart J 40(26):2128–2130CrossRef Cleland JGF, Hindricks G, Petrie M (2019) The shocking lack of evidence for implantable cardioverter defibrillators for heart failure; with or without cardiac resynchronization. Eur Heart J 40(26):2128–2130CrossRef
20.
Zurück zum Zitat McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Bělohlávek J, Böhm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukát A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O’Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjöstrand M, on behalf of the DAPA-HF Trial committees and investigators (2019) Langkilde AM Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381:1995–2008CrossRef McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Bělohlávek J, Böhm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukát A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O’Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjöstrand M, on behalf of the DAPA-HF Trial committees and investigators (2019) Langkilde AM Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381:1995–2008CrossRef
21.
Zurück zum Zitat Zeymer U, Clark AL, Barrios V, Damy T, Drożdż J, Fonseca C, Lund LH, Di Comite G, Hupfer S, Maggioni AP (2020) Management of heart failure with reduced ejection fraction in Europe: design of the ARIADNE registry. ESC Heart Fail 7(2):727–736CrossRef Zeymer U, Clark AL, Barrios V, Damy T, Drożdż J, Fonseca C, Lund LH, Di Comite G, Hupfer S, Maggioni AP (2020) Management of heart failure with reduced ejection fraction in Europe: design of the ARIADNE registry. ESC Heart Fail 7(2):727–736CrossRef
22.
Zurück zum Zitat Vaduganathan M, Claggett BL, Jhund PS, Cunningham JW, Ferreira JP, Zannad F, Packer M, Fonarow GC, McMurray JJ, Solomon SD (2020) Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Lancet 396(10244):121–128CrossRef Vaduganathan M, Claggett BL, Jhund PS, Cunningham JW, Ferreira JP, Zannad F, Packer M, Fonarow GC, McMurray JJ, Solomon SD (2020) Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Lancet 396(10244):121–128CrossRef
23.
Zurück zum Zitat McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, on behalf of the PARADIGM-HF Investigators and Committees (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371:993–1004CrossRef McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, on behalf of the PARADIGM-HF Investigators and Committees (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371:993–1004CrossRef
24.
Zurück zum Zitat Nägele H, Hashagen S, Azizi M, Behrens S, Castel MA (2007) Analysis of terminal arrhythmias stored in the memory of pacemakers from patients dying suddenly. Europace 9(6):380–384CrossRef Nägele H, Hashagen S, Azizi M, Behrens S, Castel MA (2007) Analysis of terminal arrhythmias stored in the memory of pacemakers from patients dying suddenly. Europace 9(6):380–384CrossRef
25.
Zurück zum Zitat Riesinger L, Fichtner S, Schuhmann CG, Estner HL, Czermak T, Graw M, Fischer F, Lackermair K (2019) Postmortem interrogation of cardiac implantable electrical devices may clarify time and cause of death. Int J Legal Med 133(3):883–888CrossRef Riesinger L, Fichtner S, Schuhmann CG, Estner HL, Czermak T, Graw M, Fischer F, Lackermair K (2019) Postmortem interrogation of cardiac implantable electrical devices may clarify time and cause of death. Int J Legal Med 133(3):883–888CrossRef
26.
Zurück zum Zitat Thijssen J, van Rees JB, Venlet J, Borleffs CJ, Höke U, Putter H, van der Velde ET, van Erven L, Schalij MJ (2012) The mode of death in implantable cardioverter-defibrillator and cardiac resynchronization therapy with defibrillator patients: results from routine clinical practice. Heart Rhythm 9(10):1605–1612CrossRef Thijssen J, van Rees JB, Venlet J, Borleffs CJ, Höke U, Putter H, van der Velde ET, van Erven L, Schalij MJ (2012) The mode of death in implantable cardioverter-defibrillator and cardiac resynchronization therapy with defibrillator patients: results from routine clinical practice. Heart Rhythm 9(10):1605–1612CrossRef
Metadaten
Titel
Analysis of causes of death in patients with implanted defibrillators
verfasst von
Herbert Nägele
Eike Gröene
Daniel Stierle
Matthias P. Nägele
Publikationsdatum
09.03.2021
Verlag
Springer Berlin Heidelberg
Erschienen in
Clinical Research in Cardiology / Ausgabe 6/2021
Print ISSN: 1861-0684
Elektronische ISSN: 1861-0692
DOI
https://doi.org/10.1007/s00392-021-01825-y

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Neu im Fachgebiet Kardiologie

Herzkongress ACC 2025: Diese neuen Studien stehen im Brennpunkt

Vom 29. bis 31. März findet in Chicago der Herzkongress ACC 2025 statt. Die Liste der als „Late-breaking Trials“ in den Blickpunkt gerückten neuen Studien zu wichtigen kardiologischen Themen ist wieder einmal lang.

Blutdruck am Belastungsende zeigt kardiovaskuläres Risiko

Diverse Blutdruckparameter während der Ergometrie sind schon auf ihre Aussagekraft, Mortalität und kardiovaskuläres Risiko betreffend, hin abgeklopft worden. Nun hat auch das Druckverhalten am Ende der Belastung im Fokus einer Studie gestanden.

Lp(a) wird zu selten gemessen

Laut europäischer Dyslipidämie-Leitlinie sollte die Bestimmung der Serumkonzentration von Lipoprotein (a) mindestens einmal im Leben jedes Erwachsenen erwogen werden. Tatsächlich wird die Messung selbst kardiovaskulär gefährdeten Personen nur selten zuteil.

Neue US-Leitlinie zum Management bei akutem Koronarsyndrom

In den USA ist die Leitlinie zum Management bei akutem Koronarsyndrom aktualisiert worden. In Europa erfolgte das neueste Guideline-Update dazu bereits 2023. Gehen beide Leitlinien konform oder gibt es nennenswerte Differenzen? 

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.